سعر ريفاكساريلت 10مجم 10 اقراص 2022
Rivaxarelt 10 mg- المادة الفعالة: Rivaroxaban
- Penta Pharma-Egypt
- عن طريق الفم
الفئة: مضاد للتجلط
معلومات الدواء
التفاصيل الكاملةدواعي الاستعمالUses
- Prophylaxis of deep vein thrombosis after hip or knee replacement surgeryالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatmentالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Prophylaxis of venous thromboembolism in acutely ill medical patients at risk and not at high risk of bleedingالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Prophylaxis of deep vein thrombosis after hip or knee replacement surgeryPopulation: AdultsDailyMed (U.S. National Library of Medicine)
- Reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatmentPopulation: AdultsDailyMed (U.S. National Library of Medicine)
- Prophylaxis of venous thromboembolism in acutely ill medical patients at risk and not at high risk of bleedingPopulation: AdultsDailyMed (U.S. National Library of Medicine)
الآثار الجانبيةSide effects
- The most common adverse reactions are bleeding complications.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
- Active pathological bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.نشرة دولية لنفس التركيبة · European Medicines Agency
- Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency
تحذيرات واحتياطاتWarnings & precautions
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.نشرة دولية لنفس التركيبة · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)
المثائل (7)
كل المثائل والبدائلنفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.
| الدواء | السعر | الفرق عن الأصلي |
|---|---|---|
| ريباتوكسابان 10مجم 10 اقراصRepatoxaban 10 mg 10 tabsHorus for Pharmaceutical Products · 10 mgالأرخص | السعر105ج.م10.5ج.م للوحدة | الفرق عن الأصليأرخص 75ج.م (41.7%) |
| اليبروكسابان 10 مجم 10 أقراصEliproxaban 10 mg 10 f.c. tab.Sato Pharma · قرص مغطى بطبقة رقيقة · 10 mg | السعر130ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 50ج.م (27.8%) |
| اندوريفابان 10 مجم 20 قرصAndorivaban 10 mg 20 tabletsAl Andalous Pharmaceutical Industries · أقراص · 10 mg | السعر152ج.م7.6ج.م للوحدة | الفرق عن الأصليأرخص 28ج.م (15.6%) |
| ريفافلوفاRivaflowva 10mgGypto Pharma · 10 mg | السعر210ج.م10.5ج.م للوحدة | الفرق عن الأصليأغلى 30ج.م (16.7%) |
| ريفاروسبير 10مجم 20 قرصRivarospire 10 mgInspire Pharmaceutical Company · 10 mg | السعر254ج.م12.7ج.م للوحدة | الفرق عن الأصليأغلى 74ج.م (41.1%) |
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من Penta Pharma-Egypt
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (U.S. National Library of Medicine)
- European Medicines Agency
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا